Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind placebo-controlled study of HP-6050 in delirium with psychomotor agitation and irritability
jRCT2031250324Recruiting
- Sponsor
- Hisamitsu Pharmaceutical Co., Inc.
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in delirium, psychomotor agitation and irritability comparing HP-6050 microneedle with Placebo microneedle (2 arms). Primary endpoint: Sedation scale at specified assessment timepoints. Started Oct 2025; status: recruiting.
02
Drugs
HP-6050
03
Conditions
deliriumpsychomotor agitationirritability
Beyond the preview
Go deeper on jRCT2031250324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250324.